Alseres Pharmaceuticals, Inc. (ALSE) news stock charts
Alseres Pharmaceuticals, Inc. (ALSE) Investment Summary:
We are a biotechnology company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system, or CNS. Our clinical and preclinical product candidate pipeline is based on three proprietary technology platforms: • Regenerative therapeutics program, primarily focused on nerve repair and restoring movement and sensory function in patients who have had significant loss of CNS function resulting from traumas or degenerative diseases, such as spinal cord injury, or SCI, stroke and optic nerve injury utilizing technology referred to as axon regeneration; • Molecular imaging program focused on the diagnosis of i) Parkinsonian Syndromes, or PS, including Parkinson’s Disease, or PD, ii) Attention Deficit Hyperactivity Disorder, or ADHD and iii) Dementia with Lewy Bodies, or DLB; and ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f31%2f0000950135-08-002167.html#FIS_BUSINESS"ALSERES PHARMACEUTICALS INC (ALSE:OTC)
Snapshot of ALSERES PHARMACEUTICALS INC (ALSE)
|
OPEN
$0.21
|
PREVIOUS CLOSE
$0.21
|
|
|
DAY HIGH
$0.21
|
DAY LOW
$0.21
|
|
|
52 WEEK HIGH
05/8/09 - $1.25
|
52 WEEK LOW
11/18/09 - $0.19
|
|
|
MARKET CAP
5.4M
|
AVERAGE VOLUME 10 D
10.9K
|
|
|
EPS TTM
$-0.59
|
SHARES OUTSTANDING
25.6M
|
|
|
ALSE Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ALSERES PHARMACEUTICALS INC (ALSE)
On January 4, 2010, Alseres Pharmaceuticals, Inc. has entered into Amendment No. 10 to its Manufacturing Agreement with MDS Nordion, Inc., dated as of August 9, 2000. Pursuant to Amendment No. 10, the Company and MDS Nordion has agreed to extend the term of the Manufacturing Agreement to the December 31, 2010 or December 31, 2011 after proper notice requesting such extension. The Amendment No. 10, pricing for materials provided to the Company by MDS Nordion will be increased by approximately 6% from the prices effective during 2009. The Company is seeking confidential treatment of certain portions of Amendment No. 10.
On January 8, 2010, Alseres Pharmaceuticals, Inc. announced that effective immediately its Board of Directors will be reduced from seven members to three in keeping with the companys on-going initiatives to control and further reduce its cash burn rate. It is with sincere appreciation for their efforts that the Company has accepted the resignations of directors Dr. Robert Langer, Dr. Henry Brem, Mr. John Preston and Mr. Gary Frashier. The Companys remaining directors will be Peter Savas, Michael Mullen and William Guinness.
On January 4, 2010, Alseres Pharmaceuticals, Inc. announced that Dr. Mark Pykett, President and Chief Operating Officer, left the employ of the company to become Chief Executive Officer of Talaris Advisors, LLC.
Alseres Pharmaceuticals, Inc. financial resources
ALSE Competitors
| Company | Last | Change | |
| No competitor information is available for ALSE. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | ALSE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ALSE |
||
ALSE transactions
| Type Date |
Target |
|
Private Placement
November 4, 2009 |
-- |